NVUS vs. CWBR, CNSP, CYCC, NTBL, SLRX, HSTO, CMND, BPTH, CYTO, and SNOA
Should you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include CohBar (CWBR), CNS Pharmaceuticals (CNSP), Cyclacel Pharmaceuticals (CYCC), Notable Labs (NTBL), Salarius Pharmaceuticals (SLRX), Histogen (HSTO), Clearmind Medicine (CMND), Bio-Path (BPTH), Altamira Therapeutics (CYTO), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "medical" sector.
Novus Therapeutics (NASDAQ:NVUS) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
CohBar is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
CohBar's return on equity of 0.00% beat Novus Therapeutics' return on equity.
In the previous week, Novus Therapeutics' average media sentiment score of 0.00 equaled CohBar'saverage media sentiment score.
Novus Therapeutics received 234 more outperform votes than CohBar when rated by MarketBeat users. However, 72.00% of users gave CohBar an outperform vote while only 66.84% of users gave Novus Therapeutics an outperform vote.
2.5% of CohBar shares are owned by institutional investors. 2.2% of Novus Therapeutics shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
CohBar beats Novus Therapeutics on 7 of the 10 factors compared between the two stocks.
Get Novus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novus Therapeutics Competitors List
Related Companies and Tools
